Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

Taşlı, Neslihan; GÖNEN, ZEYNEP; Kırbaş, Oğuz; Gökdemir, Nur; Bozkurt, Batuhan; Bayrakcı, Buse; Sağraç, Derya; Taşkan, Ezgi; Demir, Sevda; Ekimci Gürcan, Nur; Bayındır Bilgiç, Melike; Bayrak, Ömer; Yetişkin, Hazel; Kaplan, Büşra; Pavel, Shaikh; Dinç, Gökçen; Serhatlı, Müge; Çakırca, Gamze; Eken, Ahmet; Aslan, Vedat; Yay, Mehmet; Karakukcu, Musa; Unal, Ekrem; Gül, Fethi; Basaran, Kemal; Ozkul, Yusuf; Şahin, Fikrettin; Jones, Olcay; Tekin, Şaban; Özdarendeli, Aykut; Cetin, Mustafa

doi:10.3389/fimmu.2022.824378

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

Copy For Citation

Taşlı N. P., GÖNEN Z. B., Kırbaş O. K., Gökdemir N. S., Bozkurt B. T., Bayrakcı B., ...More

Frontiers in Immunology, vol.13, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 13
Publication Date: 2022
Doi Number: 10.3389/fimmu.2022.824378
Journal Name: Frontiers in Immunology
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Directory of Open Access Journals
Keywords: exosome, extracellular vehicles (EVs), COVID-19, SARS-CoV-2, convalescence plasma, viral treatment, ACUTE RESPIRATORY SYNDROME, COVID-19, VENTILATION, RESPONSES, VESICLES
Kayseri University Affiliated: No

Abstract

Copyright © 2022 Taşlı, Gönen, Kırbaş, Gökdemir, Bozkurt, Bayrakcı, Sağraç, Taşkan, Demir, Ekimci Gürcan, Bayındır Bilgiç, Bayrak, Yetişkin, Kaplan, Pavel, Dinç, Serhatlı, Çakırca, Eken, Aslan, Yay, Karakukcu, Unal, Gül, Basaran, Ozkul, Şahin, Jones, Tekin, Özdarendeli and Cetin.The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.